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The mechanistic target of rapamycin (mTOR) signaling pathway regulates many fundamental metabolic and
physiological processes, including lipid metabolism. We explore recent findings on the role of mTOR in lipid
homeostasis, with an emphasis on recent findings from in vivo models regarding the role of mTORC2 in
lipolysis, lipogenesis, and adipogenesis.An Introduction to mTOR
The mechanistic target of rapamycin (mTOR) is a phos-
phatidylinositol 3-kinase (PI3K)-like serine/threonine protein
kinase that is evolutionarily conserved in all eukaryotes.
mTOR is found in two complexes, each with distinct protein
components as well as substrates. mTOR complex 1
(mTORC1), which is acutely sensitive to rapamycin, regulates
processes such as ribosomal biogenesis, cap-dependent
translation, lysosomal biogenesis, and autophagy via sub-
strates that include S6 kinase (S6K), 4E-binding protein 1
(4E-BP1), TFEB1, and Ulk1. mTORC1 activity is regulated in
part by the Rag family of guanosine triphosphatases
(GTPases), which promote the localization of mTORC1 to the
lysosome in response to amino acids and glucose. At the lyso-
some, mTORC1 is activated by guanosine triphosphate (GTP)-
bound Ras homolog enriched in brain (Rheb), which is itself
regulated by the tuberous sclerosis complex (TSC1/2) in
response to AMP-activated protein kinase (AMPK), oxygen,
and growth factor signaling. mTOR complex 2 (mTORC2),
which is resistant to acute rapamycin treatment but can be dis-
rupted by chronic rapamycin treatment in tissue culture as well
as in vivo, is sensitive to growth factor signaling and regulates
targets downstream of the insulin/insulin-like growth factor 1
(IGF-1) receptor via substrates that include Akt, serum/gluco-
corticoid-regulated kinase (SGK), and protein kinase Ca
(PKCa). For a more complete treatment of the regulation of
mTOR signaling in response to nutrients, we refer the reader
to a recent comprehensive review (Laplante and Sabatini,
2012).
The past several years have seen an explosion of interest in
the mTOR signaling pathway, spurred in large part by the
finding that inhibition of mTORC1 signaling can significantly
increase lifespan and protect from age-related diseases in
mouse models (reviewed in Lamming et al., 2013). Genetically
engineered mouse models have significantly added to our
understanding of the role of mTOR in mammalian physiology.
It is clear that mTOR signaling regulates lipid homeostasis,
as treatment of rodents or humans with rapamycin leads to
hyperlipidemia and hypercholesterolemia. This minireview will
focus on the role of mTORC1 and mTORC2 in lipid physiology
(Figure 1A).Both mTOR Complexes Play a Role in Adipogenesis
It has been appreciated for some time that mTORC1 plays a role
in adipogenesis. Tissue culture experiments starting in 2001
have shown that inhibition of mTORC1 signaling genetically or
with rapamycin impairs adipogenesis, while increasingmTORC1
signaling by small interfering RNA (siRNA) against TSC1/2 pro-
motes adipogenesis. Deletion of TSC2 likewise promotes adipo-
cyte differentiation (Zhang et al., 2009). This effect is mediated in
part by 4E-BP1 via the regulation of the translation of peroxi-
some proliferator-activated receptor g (PPARg), but in vivo
experiments have also pointed to an important role for S6K.
S6K1 knockout mice show resistance to weight gain on a high-
fat diet, due to impaired generation of adipocytes (Carnevalli
et al., 2010). Mice with an adipose-specific deletion of RAPTOR,
which is required for mTORC1 activity, phenocopy the S6K1
knockout mice (Polak et al., 2008). They are lighter, lean, and
resistant to weight gain on a high-fat diet. Furthermore, their
adipocytes are both smaller and less numerous. This was true
even though RAPTOR expression was lost only in mature adipo-
cytes. Finally, as discussed in the next section, mTORC1 may
also regulate adipogenesis in part via the regulation of the sterol
regulatory element-binding proteins (SREBPs).
While it was initially assumed that mTORC2 also played a role
in adipogenesis, as it is upstream of Akt, initial studies of adi-
pose-specific RICTOR knockout mice observed no defects in
adipogenesis (Cybulski et al., 2009; Kumar et al., 2010). How-
ever, Yao and colleagues have recently uncovered a role for
mTORC2 in adipogenesis (Yao et al., 2013). They discovered
that the phosphorylation of Akt S473 by mTORC2 was depen-
dent upon the interaction of Akt with phosphorylated BTSA (a
BSD domain-containing protein). Moreover, they found that
BSTA is a direct substrate of mTORC2, and phosphorylation of
BSTA promotes the interaction with Akt, leading to its subse-
quent phosphorylation at S473. Embryonic stem cells lacking
BSTA have defective Akt S473 phosphorylation and are not
capable of differentiating into adipocytes. Yao et al. (2013)
discovered that this was due to induction of the transcription fac-
tor FoxC2, which inhibits white adipogenesis while potentiating
brown adipogenesis. The combination of these studies suggests
that mTORC2 may be essential for early adipogenesis but does
not affect adipogenesis when excised in mature adipocytes.Cell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc. 465
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Figure 1. mTOR in Lipid Homeostasis
(A) A model of the actions of mTORC1 and mTORC2 in lipid metabolism, including adipogenesis, ketogenesis, lipogenesis, and lipolysis. The mechanism by
which mTORC2 regulates lipogenesis and lipolysis are not currently known, although Akt may be involved in the regulation of lipogenesis.
(B) Representative oil red O-stained liver sections from wild-type or L-RicKO mice on a high-fat diet for 25 weeks.
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TOR) interacts with both mTORC1 and mTORC2 (Peterson
et al., 2009). DEPTOR is part of a quantitative trait locus linked
to obesity in mice, and it was recently observed that overexpres-
sion of DEPTOR leads to the accumulation of white adipose tis-
sue (Laplante et al., 2012). Increased expression of DEPTOR
stimulates adipogenesis in vitro, in part by activating PPARg
(Laplante et al., 2012). DEPTOR expression also relieves the
negative effect of mTORC1 on insulin signaling, activating the
adipogenic functions of Akt. DEPTOR expression is significantly
elevated in the adipose tissue of obese humans, suggesting that
this mechanismmay be conserved frommouse toman (Laplante
et al., 2012).
Hepatic mTORC1 Regulates Ketogenesis and
Lipogenesis
It has long been known that during fasting, ketone bodies are
produced in the liver as an energy source for peripheral tissues,
including the brain. While studying mice with a liver-specific
deletion of TSC1, resulting in the constitutive activation of
mTORC1, Sengupta et al. (2010) observed defective ketogen-
esis when fasted. Following a 24 hr fast, these mice had less
than half the level of total serum ketones of control mice
(Sengupta et al., 2010). The livers of aged mice similarly have
increased mTORC1 activity and a defect in ketogenesis, which
can be corrected by deletion of hepatic RAPTOR (Sengupta
et al., 2010). While the mechanism was elusive, they found that
mTORC1 regulates PPARa activity and gene expression by pro-
moting the nuclear localization of nuclear receptor corepressor 1
(NCoR1), a corepressor that interacts with PPARa. Kim et al.
(2012) recently determined that S6K2, an effector of mTORC1466 Cell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc.that is highly homologous to S6K1, regulates the nuclear locali-
zation of NCoR1.
In 2008, Portsmann and colleagues were the first to identify a
role for mTORC1 in lipogenesis, with the finding that rapamycin
blocks the expression of genes involved in lipogenesis and
impairs the nuclear accumulation of the SREBPs (Porstmann
et al., 2008). Subsequent work by Du¨vel and colleagues identi-
fied the sterol regulatory element as the most highly enriched
DNA motif in a gene expression study of rapamycin-sensitive
genes (Du¨vel et al., 2010). Although the exact mechanism by
which SREBP1 and SREBP2 are regulated by mTORC1 is
unclear, it is believed to be mediated by S6K1 (Du¨vel et al.,
2010). Using a small molecule inhibitor of S6K, Owen et al.
(2012) find that the transcriptional regulation of SREBP1c by
insulin is not dependent on S6K, whereas posttranscriptional
processing of SREBP1c is S6K dependent.
mTORC1 may also regulate the SREBP transcriptional
network via the negative regulation of lipin1 (Peterson et al.,
2011). Lipin1 is an mTORC1 substrate with multiple phosphory-
lation sites, including both rapamycin-sensitive sites and sites
phosphorylated by mTORC1 that are relatively insensitive to ra-
pamycin. Phosphorylation of lipin1 by mTORC1 regulates its
subcellular localization, with phosphorylated lipin1 residing in
the cytoplasm and dephosphorylated lipin1 accumulating in
the nucleus. Nuclear lipin1 represses SREBP-dependent gene
transcription by reducing the nuclear SREBP protein levels
(Peterson et al., 2011). Despite these recent advances in under-
standing how mTORC1 regulates lipogenesis, the molecular
mechanisms by which S6K or lipin1 regulate SREBPs remains
unknown. It should also be emphasized that mTORC1 signaling
is essential, but not sufficient, to activate SREBP1c and hepatic
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increased mTORC1 activity but have defective SREBP1c activa-
tion and lipogenesis, due to an attenuation of Akt signaling
(Yecies et al., 2011). As discussed below, signaling through
mTORC2 is also essential for lipogenesis.mTORC2, a Newly Identified Regulator of Lipid
Homeostasis
In comparison to mTORC1, much less is known about the sub-
strates and functions of mTORC2, as it was discovered more
recently. The best-characterized substrates of mTORC2 are
members of the AGC family of kinases, including Akt, SGK1,
and PKCa. mTORC2 mediates Akt activity by directly phosphor-
ylating Akt S473 in response to growth factor signaling and also
phosphorylates T450 cotranslationally. As Akt regulates
mTORC1 via phosphorylation of TSC2 and PRAS40, mTORC2
indirectly regulates mTORC1 in response to growth factor
signaling. mTORC2 is also required for phosphorylation of sites
on PKCa as well as SGK1. Additional substrates of mTORC2
may also include PKCd and are still being identified using phos-
phoproteomic techniques.
The regulation of Akt and SGK1 by mTORC2 suggests that
mTORC2may play a crucial role in the regulation of metabolism.
Data from C. elegans have supported this concept, as RICTOR-
null worms have high levels of body fat on either a normal or high-
fat diet (Jones et al., 2009; Soukas et al., 2009). While the exact
mechanism underlying these effects is not clear, reports from
both the Ashrafi and Ruvkun labs agree that these effects are
at least partially dependent on SGK1 (Jones et al., 2009; Soukas
et al., 2009).
mTORC2 activity is required for embryonic development, and
the role of mTORC2 in mammalian metabolism has therefore
been elucidated only recently. Moreover, some of the first mouse
models with tissue-specific inactivation of mTORC2, achieved
through the use of mice expressing a conditional allele of
RICTOR, showed minimal phenotypes. Bentzinger and
colleagues found that mice lacking skeletal muscle Rictor
(M-RicKO) had normal activation of Akt and normal phosphory-
lation of Akt T308, despite decreased phosphorylation of Akt
S473 (Bentzinger et al., 2008). Subsequent studies of the role
of mTORC2 in other tissues suggest that while mTORC2 may
be dispensable for Akt activity in muscle, it is required for Akt
activity in liver and adipose tissue (Kumar et al., 2008; Lamming
et al., 2012; Yuan et al., 2012). While an in vivo role for mTORC2
in skeletal muscle has not been identified, in vitro data suggest
that mTORC2 may play a role in the rapamycin-mediated
skeletal muscle insulin resistance (Ye et al., 2012).Adipose mTORC2 Regulates Lipolysis
Adipose-specific inactivation of mTORC2 has been researched
independently by two groups, with largely similar conclusions.
Adipose-specific deletion of RICTOR (A-RicKO) mice trends
toward being slightly heavier with significantly more lean mass
(Cybulski et al., 2009). On a high-fat diet, these trends are exag-
gerated, with the livers of mTORC2 adipose knockout mice
weighing 75%more than the livers of control mice after 10weeks
on a high-fat diet (Cybulski et al., 2009). The increased weight of
these livers was partially due to a significant elevation in hepatictriglycerides compared with control mice, with a concomitant
increase in hepatic steatosis.
While Cybulski et al. (2009) found A-RicKOmice to be glucose
tolerant, Kumar et al. (2010) found mTORC2 adipose knockout
mice to be quite severely glucose intolerant. This apparent
discrepancy in findings is easily explained by the different ages
of the mice, as Kumar examined significantly older mice (greater
than 9 months of age). At this age, A-RicKO mice displayed both
adipose and skeletal muscle insulin resistance, likely due to sig-
nificant lipid deposition in skeletal muscle (Kumar et al., 2010).
Kumar and colleagues also found increased hepatic lipid depo-
sition and steatosis in young and old A-RicKO mouse livers.
These results suggest that many of themetabolic consequences
of disruptingmTORC2 in adipose tissue are driven by lipid depo-
sition in other tissues.
Interestingly, Kumar and colleagues found that mTORC2 reg-
ulates the insulin-mediated suppression of lipolysis in adipose
tissue. Lipolysis, the breakdown of lipids into free fatty acids
(FFA), should normally be suppressed when nutrients are high,
but this does not occur in A-RicKO mice (Kumar et al., 2010).
Moreover, A-RicKO mice have high levels of FFA, indicating
that the absence of mTORC2 activity results in higher basal
levels of lipolysis. While the mechanism has not been fully
worked out, mTORC2 may normally regulate lipolysis by inhibit-
ing the activation of PKA. In the absence of mTORC2, PKA is
activated and phosphorylates hormone-sensitive lipase,
activating its lipolytic activity (Kumar et al., 2010). Finally,
mTORC2 may also promote glucose uptake into adipose tissue,
as mTORC2 adipose knockout mice have decreased glucose
uptake (Kumar et al., 2010). However, this will require further
study, as adult mice in which Rictor has been depleted in the
whole body show increased glucose uptake into Rictor-depleted
adipose tissue (Lamming et al., 2012).
Hepatic mTORC2 Regulates Lipogenesis
In the past year, some exciting lessons have been learned about
the role of mTORC2 in hepatic tissue through the use of mice
with a liver-specific deletion of RICTOR (L-RicKO). One of the
most prominent phenotypes of these mice is hepatic insulin
resistance that leads to increased gluconeogenesis (Lamming
et al., 2012). However, while hepatic insulin resistance is often
associated with fatty liver, L-RicKO mice are actually protected
against high-fat-diet-induced fatty liver (Hagiwara et al., 2012;
Yuan et al., 2012). Hagiwara et al. (2012) observed that in addi-
tion to increased gluconeogenesis, hepatocytes from L-RicKO
mice have decreased glucose uptake, likely as a result of
decreased expression of glucokinase. Moreover, L-RiKO mice
have decreased levels of triglycerides, and Hagiwara et al.
(2012) as well as Yuan et al. (2012) theorized that mTORC2 is
required for hepatic lipogenesis.
Indeed, both groups found that insulin-stimulated hepatic lipo-
genesis was significantly impaired in L-RicKO mice. In the
absence of mTORC2, hepatic expression of many key lipid syn-
thesis genes, including acetyl-CoA carboxylase and fatty acid
synthase, was reduced by 50% or more (Hagiwara et al., 2012;
Yuan et al., 2012). L-RicKO mice also have decreased hepatic
expression of SREBP1c and PPARg. Interestingly, L-RicKO
mice also have increased expression of genes related to fatty
acid oxidation, including PPARa, and decreased expression ofCell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc. 467
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deficient livers is therefore likely due to a combination of
decreased lipid synthesis, decreased lipid uptake, and increased
lipid consumption.
Both Hagiwara et al. (2012) and Yuan et al. (2012) performed
in vivo genetic manipulations to try to determine themechanisms
behind the effects of Rictor deletion on gluconeogenesis and
lipogenesis. Both groups found that expression of constitutively
active Akt was sufficient to inhibit gluconeogenesis and restore
normal glucose tolerance. However, while Hagiwara et al.
(2012) reported that constitutively active Akt was sufficient to
restore lipogenesis, Yuan et al. (2012) found that constitutively
active Akt did not rescue the lipogenesis defect. The difference
between these results may be explained by the fact that Hagi-
wara et al. (2012) observed gene expression and lipid synthesis
in hepatocyte culture, while Yuan et al. (2012) looked at the effect
of constitutively active Akt expression on serum triglycerides and
hepatic triglyceride accumulation in vivo. In vivo, Yuan et al.
(2012) demonstrate that activation of Akt alone is insufficient to
correct the lipogenesis defect of L-RicKO mice, and they sug-
gest that this may be due to decreased mTORC1 activity toward
lipin1 in vivo in L-RicKO mice. The observations of both groups
are internally consistent with the observed effects on mTORC1
signaling in each system, as Hagiwara et al. (2012) did not
observe decreased mTORC1 signaling in hepatocyte culture.Conclusions
mTOR is a central regulator of lipid metabolism, regulating not
only lipogenesis and lipolysis, but also adipogenesis. Most
recently, mTORC2 in particular has emerged as a key controller
of lipid metabolism, regulating lipogenesis in the liver, regulating
lipolysis in white adipose tissue, and controlling adipogenesis.
These findings are summarized in Figure 1A. From a clinical
perspective, the development of mTORC1-specific inhibitors
may significantly decrease the side effects now associated
with rapamycin. Specific inhibition of mTORC2 has the potential
for real gains in the treatment of obesity and nonalcoholic fatty
liver disease (NAFLD). As shown in Figure 1B, deletion of hepatic
Rictor, resulting in the inhibition of mTORC2 signaling, provides
dramatic protection against high-fat-diet-induced fatty liver.
Clinically, inhibitionofhepaticmTORC2maypromote themeta-
bolismof excesshepatic lipids,while inhibitionofmTORC2during
adipocyte differentiation could promote the gain of brown adi-
pose tissue. Both of these properties could potentially be advan-
tageous from the standpoint of treating obesity. However the side
effects ofmTORC2 inhibition, including hepatic insulin resistance,
which may account for an increased incidence of new-onset dia-
betes in patients treated with rapamycin, suggests that direct
inhibition of mTORC2 will be undesirable. Identification of the
ultimate mechanisms downstream of mTORC2 that regulate lipid
metabolism and the generation of new compounds that directly
affect thesemechanismswithoutdisturbingglucosehomeostasis
will be vital in safely translating these findings into the clinic.ACKNOWLEDGMENTS
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